IFITM1 anticorps (C-Term)

N° du produit ABIN1680390

Détail du produit anti-IFITM1 anticorps

Antigène: IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IFITM1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Séquence: CCLGFIAFAY SVKSRDRKMV GDVTGAQAYA STAKCLNIWA LILGILMTIG FILLLVFGSV TVYHIMLQII QEKRGY

Réactivité croisée: Humain, Souris

Attributs du produit: Polyclonal Antibodies

Purification: Affinity purification

Immunogène: A synthetic peptide corresponding to a sequence within amino acids 50 to the C-terminus of human IFITM1 (NP_003632.3).

Isotype: IgG

Information d'application

Indications d'application: WB,1:200 - 1:2000,IHC,1:50 - 1:200

Restrictions: For Research Use only

Stockage

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Références pour anticorps anti-IFITM1 (ABIN1680390)

Teng, Luo, Yu, Chen, Huang, Chen, Xie, Zeng, Luo, Xiong, Liu, Hou, Feng: "CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells." dans: Genes and immunity, (2018) (PubMed).

Détails sur IFITM1

Antigène: IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))

Autre désignation: IFITM1 (IFITM1 Produits)

Synonymes: anticorps 9-27, anticorps CD225, anticorps DSPA2a, anticorps IFI17, anticorps LEU13, anticorps 1110036C17Rik, anticorps Mil-2, anticorps Mil2, anticorps interferon induced transmembrane protein 1, anticorps interferon induced transmembrane protein 1 (9-27), anticorps Ifitm1, anticorps IFITM1

Sujet: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1 and hepatitis C virus (HCV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM1,9-27,CD225,DSPA2a,IFI17,LEU13,Cancer,Tumor biomarkers,Tumor suppressors,p53 pathway,Signal Transduction,Immunology & Inflammation,CD markers,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,Stem Cells,IFITM1

Poids moléculaire: 13 kDa

ID gène: 8519

UniProt: P13164